BN82451B ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
8	ハンチントン病	2

8. ハンチントン病

---

臨床試験数 : 242 /  薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02231580 (ClinicalTrials.gov)	September 1, 2014	2/9/2014	Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients	A Dose Escalation, Proof of Concept, Phase IIa Study to Investigate the Safety and Tolerability, the Pharmacokinetic and the Pharmacodynamic of BN82451B, Administered Twice Daily Over 4 Weeks, in Male Patients With Huntington's Disease	Huntington's Disease	Drug: BN82451B;Drug: Placebo	Ipsen	NULL	Terminated	20 Years	70 Years	Male	17	Phase 2	Germany
2	EUCTR2013-002899-41-DE (EUCTR)	28/04/2014	24/01/2014	Study to assess the effects of BN82451B and how it is absorbed, distributed and eliminated in the body, when it is given for 4 weeks to men suffering from Hungtington's disease	A dose escalation, proof of concept, phase IIa study to investigate the safety and tolerability, the pharmacokinetic and thepharmacodynamic of BN82451B, administered twice daily over 4 weeks, in male patients with Huntington’s disease	Huntington's disease MedDRA version: 18.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: BN8251B INN or Proposed INN: N/A Other descriptive name: BN82451B Product Name: BN8251B INN or Proposed INN: N/A Other descriptive name: BN82451B	Ipsen Pharma	NULL	Not Recruiting			Female: no Male: yes		Phase 2	Germany